Revenio Group Corporation: Revenio Group Corporation applies for listing of stock options 2015 C

Report this content

Revenio Group Corporation, Stock Exchange Release, May 29, 2019 at 11.00

Revenio Group Corporation applies for listing of stock options 2015 C

Revenio Group Corporation will apply for the listing of its series C stock options, complying with its 2015 option scheme, on the Nasdaq Helsinki Ltd (Firsth North) as of June 3, 2019.

The total number of the C series stock options under the 2015 option scheme is 50,000. Each option right entitles its holder to subscribe to three (3) Revenio Group Corporation shares. The maximum number of new shares to be issued is 150 000.

At the moment, the share subscription price under the C series option rights is EUR 12.78 per share. In accordance with the terms and conditions of the option scheme, the subscription price has been reduced by the amount of dividends decided before the share subscription, on the record date of each dividend payment. In accordance with the terms and conditions of the option scheme, the share subscription period for series C option rights begins on May 31, 2019. The option rights are freely transferable as from that date. The subscription period will end on May 31, 2021. The option holders can subscribe the shares during the subscription period by giving the payment and subscription details to their own bank.

The grounds for the granting of the 2015 option rights and the original terms and conditions were published in a stock exchange release on August 10, 2014. The terms and conditions of the option scheme 2015, as well as the approval schedule for share subscriptions under the option rights are available in full on the company’s website at

Revenio Group Corporation

Board of Directors

For further information, please contact:

Timo Hildén, CEO, tel.  +358 40 580 4774


Nasdaq Helsinki Oy

Financial Supervisory Authority (FIN-FSA)

Principal media

The Revenio Group in brief

Revenio is a globally operating health technology corporation and a global leader in ophthalmic products.

The Revenio Group consists of Icare Finland Oy, Icare USA Inc., Revenio Italy S.R.L, CenterVue SpA, CenterVue Inc, Revenio Research Oy sekä Oscare Medical Oy. 

The common denominator of Revenio's business is patient driven screening, monitoring and the global need for cost savings in healthcare through preventive healthcare. Revenio seeks strong growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The objective is to create better quality of life through health technology solutions that enable more efficient diagnostics. The focus of Group is on the early detection and the management of sight-threatening pathologies such as Glaucoma, Diabetic Retinopathy and Macular Degeneration. Revenio Research, in turn, focuses on the commercialization of systems supporting the diagnosis and treatment of skin cancer and asthma.

In 2018, the Revenio Group's net sales totaled EUR 30.7 million, with its operating margin standing at 33.3%. Revenio Group Corporation is listed on Nasdaq Helsinki.